Microbot Medical (NASDAQ:MBOT) Shares Cross Above Two Hundred Day Moving Average - Here's What Happened

Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report)'s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.74 and traded as high as $2.90. Microbot Medical shares last traded at $2.68, with a volume of 2,094,084 shares changing hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and issued a $9.00 target price on shares of Microbot Medical in a research note on Thursday, April 10th.

Microbot Medical Trading Down 3.7%

The stock has a market cap of $93.86 million, a P/E ratio of -3.22 and a beta of 1.15. The firm's 50-day simple moving average is $2.24 and its 200 day simple moving average is $1.75.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.07. On average, analysts anticipate that Microbot Medical Inc. will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Microbot Medical

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in shares of Microbot Medical by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock worth $160,000 after acquiring an additional 10,442 shares in the last quarter. Virtu Financial LLC acquired a new stake in Microbot Medical in the first quarter valued at approximately $42,000. Goldman Sachs Group Inc. acquired a new stake in Microbot Medical in the first quarter valued at approximately $57,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Microbot Medical in the fourth quarter worth $118,000. Institutional investors and hedge funds own 16.30% of the company's stock.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.